Heather A. Cooke
Research Subjects
Heather A. Cooke has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Steven D. Bruner
‡Division of Pharmaceutical Sciences, ∥University of Wisconsin National Cooperative Drug Discovery Group, **Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53705, the §Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, Peoples Republic of China, and the ¶Department of Chemistry, Boston College, Chestnut Hill, Massachusetts 02467
3 shared publications- Wilfred A. van der Donk
University of Illinois at Urbana-Champaign
3 shared publications Ben Shen
Department of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, Massachusetts 02467, Department of Chemistry, Division of Pharmaceutical Sciences, and University of Wisconsin National Cooperative Drug Discovery Group, University of WisconsinMadison, Madison, Wisconsin 53705
2 shared publications- Bradley S. Evans
Donald Danforth Plant Science Center
2 shared publications Jian Zhang
‡Division of Pharmaceutical Sciences, ∥University of Wisconsin National Cooperative Drug Discovery Group, **Department of Chemistry, University of Wisconsin, Madison, Wisconsin 53705, the §Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, Peoples Republic of China, and the ¶Department of Chemistry, Boston College, Chestnut Hill, Massachusetts 02467
2 shared publicationsRobert M. Cicchillo
Institute for Genomic Biology, University of Illinois, 1206 West Gregory, Urbana, IL 61801, USA
2 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2546554
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays an important role in microglial function and has been genetically linked to Alzheimer's disease. Activation of TREM2 signaling may contribute to protection against neurotoxic effects of amyloid. Numerous TREM2 activating antibodies have been shown to modulate downstream microglial functions to different degrees, with mixed results in preclinical models and in the clinic. We sought to generate an effectorless agonistic antibody that acted solely through TREM2 engagement with sufficient potency to activate TREM2 in the brain. Our approach focused on building a multivalent biparatopic TREM2 antibody that could mimic the higher order clustering induced by native polyanionic ligands of TREM2. We describe our screening strategy and findings that led to the discovery of a potential therapeutic molecule composed of antibodies selected for optimal affinity, binding epitopes, and geometry. The most productive antibody pair was selected from a common light chain yeast-display library, which required multiple rounds of affinity maturation. Lead antibody candidates were converted into asymmetric tetravalent bispecifics via controlled Fab-arm exchange and subsequently screened in signaling assays. The most productive antibody pair was reengineered into a symmetric tetravalent format, increasing potency and simplifying development. This molecule exhibited higher efficacy and potency in signaling assays than other antibody formats tested and elicited TREM2-mediated chemokine responses in vivo. Our results demonstrate a biparatopic strategy for producing a high potency TREM2 agonistic antibody with low effector function that can modulate TREM2 signaling in vitro and brain pharmacodynamic responses in vivo.
- 13 August 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2546554
Open AccessBuilding a potent TREM2 agonistic, biparatopic, common light chain antibody
Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays an important role in microglial function and has been genetically linked to Alzheimer's disease. Activation of TREM2 signaling may contribute to protection against neurotoxic effects of amyloid. Numerous TREM2 activating antibodies have been shown to modulate downstream microglial functions to different degrees, with mixed results in preclinical models and in the clinic. We sought to generate an effectorless agonistic antibody that acted solely through TREM2 engagement with sufficient potency to activate TREM2 in the brain. Our approach focused on building a multivalent biparatopic TREM2 antibody that could mimic the higher order clustering induced by native polyanionic ligands of TREM2. We describe our screening strategy and findings that led to the discovery of a potential therapeutic molecule composed of antibodies selected for optimal affinity, binding epitopes, and geometry. The most productive antibody pair was selected from a common light chain yeast-display library, which required multiple rounds of affinity maturation. Lead antibody candidates were converted into asymmetric tetravalent bispecifics via controlled Fab-arm exchange and subsequently screened in signaling assays. The most productive antibody pair was reengineered into a symmetric tetravalent format, increasing potency and simplifying development. This molecule exhibited higher efficacy and potency in signaling assays than other antibody formats tested and elicited TREM2-mediated chemokine responses in vivo. Our results demonstrate a biparatopic strategy for producing a high potency TREM2 agonistic antibody with low effector function that can modulate TREM2 signaling in vitro and brain pharmacodynamic responses in vivo.
- Open Access
- 13 September 2012
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 134 (38) , 15660-15663
Mechanistic Investigation of Methylphosphonate Synthase, a Non-Heme Iron-Dependent Oxygenase
Methylphosphonate synthase is a non-heme iron-dependent oxygenase that converts 2-hydroxyethylphosphonate (2-HEP) to methylphosphonate. On the basis of experiments with two enantiomers of a substrate analog, 2-hydroxypropylphosphonate, catalysis is proposed to commence with stereospecific abstraction of the pro-S hydrogen on C2 of the substrate. Experiments with isotopologues of 2-HEP indicate stereospecific hydrogen transfer of the pro-R hydrogen at C2 of the substrate to the methyl group of methylphosphonate. Kinetic studies with these substrate isotopologues reveal that neither hydrogen transfer is rate limiting under saturating substrate conditions. A mechanism is proposed that is consistent with the available data.
- 13 September 2012
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 134 (38) , 15660-15663
Open AccessMechanistic Investigation of Methylphosphonate Synthase, a Non-Heme Iron-Dependent Oxygenase
Methylphosphonate synthase is a non-heme iron-dependent oxygenase that converts 2-hydroxyethylphosphonate (2-HEP) to methylphosphonate. On the basis of experiments with two enantiomers of a substrate analog, 2-hydroxypropylphosphonate, catalysis is proposed to commence with stereospecific abstraction of the pro-S hydrogen on C2 of the substrate. Experiments with isotopologues of 2-HEP indicate stereospecific hydrogen transfer of the pro-R hydrogen at C2 of the substrate to the methyl group of methylphosphonate. Kinetic studies with these substrate isotopologues reveal that neither hydrogen transfer is rate limiting under saturating substrate conditions. A mechanism is proposed that is consistent with the available data.
- Top Cited Papers
- 31 August 2012
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 337 (6098) , 1104-1107
Synthesis of Methylphosphonic Acid by Marine Microbes: A Source for Methane in the Aerobic Ocean
Ocean Methane: Is methylphosphonate a natural product? If it is, then its catabolism by microrganisms seeking phosphorus might explain the ubiquity of methane in the oceans. Anaerobic Archaea, so far, are the only significant source of methane known. Thus, Metcalf et al. (p. 1104 ) looked for evidence of methylphosphonate biochemistry in the widespread archaeon Nitrosopumilus maritimus. The organism can synthesize C-P bonds using phosphoenolpyruvate mutase. By using its gene, ppm , as a marker, a possible phosphonate biosynthesis gene cluster was identified, and adjacent to this a gene for a cupin was found. Together with Fe(II) and O 2 the cupin catalyzed the production of methylphosphonate and formate. Homologs of the cupin gene are found in a wide range of common marine microbes, including Pelagibacter ubique and Prochlorococcus.
- 31 August 2012
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 337 (6098) , 1104-1107
Top Cited PapersSynthesis of Methylphosphonic Acid by Marine Microbes: A Source for Methane in the Aerobic Ocean
Ocean Methane: Is methylphosphonate a natural product? If it is, then its catabolism by microrganisms seeking phosphorus might explain the ubiquity of methane in the oceans. Anaerobic Archaea, so far, are the only significant source of methane known. Thus, Metcalf et al. (p. 1104 ) looked for evidence of methylphosphonate biochemistry in the widespread archaeon Nitrosopumilus maritimus. The organism can synthesize C-P bonds using phosphoenolpyruvate mutase. By using its gene, ppm , as a marker, a possible phosphonate biosynthesis gene cluster was identified, and adjacent to this a gene for a cupin was found. Together with Fe(II) and O 2 the cupin catalyzed the production of methylphosphonate and formate. Homologs of the cupin gene are found in a wide range of common marine microbes, including Pelagibacter ubique and Prochlorococcus.
- Open Access
- 8 July 2011
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (30) , 6598-6605
Mechanism and Substrate Recognition of 2-Hydroxyethylphosphonate Dioxygenase
HEPD belongs to the superfamily of 2-His-1-carboxylate non-heme iron-dependent dioxygenases. It converts 2-hydroxyethylphosphonate (2-HEP) to hydroxymethylphosphonate (HMP) and formate. Previously postulated mechanisms for the reaction catalyzed by HEPD cannot explain its conversion of 1-HEP to acetylphosphate. Alternative mechanisms that involve either phosphite or methylphosphonate as intermediates, which potentially explain all experimental studies including isotope labeling experiments and use of substrate analogues, were investigated. The results of these studies reveal that these alternative mechanisms are not correct. Site-directed mutagenesis studies of Lys16, Arg90, and Tyr98 support roles of these residues in binding of 2-HEP. Mutation of Lys16 to Ala resulted in an inactive enzyme, whereas mutation of Arg90 to Ala or Tyr98 to Phe greatly decreased kcat/Km,2-HEP. Furthermore, the latter mutants could not be saturated in O2. These results suggest that proper binding of 2-HEP is important for O2 activation and that the enzyme uses a compulsory binding order with 2-HEP binding before O2. The Y98F mutant produces methylphosphonate as a minor side product providing indirect support for the proposal that the last step during catalysis involves a ferric hydroxide reacting with a methylphosphonate radical.
- 8 July 2011
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (30) , 6598-6605
Open AccessMechanism and Substrate Recognition of 2-Hydroxyethylphosphonate Dioxygenase
HEPD belongs to the superfamily of 2-His-1-carboxylate non-heme iron-dependent dioxygenases. It converts 2-hydroxyethylphosphonate (2-HEP) to hydroxymethylphosphonate (HMP) and formate. Previously postulated mechanisms for the reaction catalyzed by HEPD cannot explain its conversion of 1-HEP to acetylphosphate. Alternative mechanisms that involve either phosphite or methylphosphonate as intermediates, which potentially explain all experimental studies including isotope labeling experiments and use of substrate analogues, were investigated. The results of these studies reveal that these alternative mechanisms are not correct. Site-directed mutagenesis studies of Lys16, Arg90, and Tyr98 support roles of these residues in binding of 2-HEP. Mutation of Lys16 to Ala resulted in an inactive enzyme, whereas mutation of Arg90 to Ala or Tyr98 to Phe greatly decreased kcat/Km,2-HEP. Furthermore, the latter mutants could not be saturated in O2. These results suggest that proper binding of 2-HEP is important for O2 activation and that the enzyme uses a compulsory binding order with 2-HEP binding before O2. The Y98F mutant produces methylphosphonate as a minor side product providing indirect support for the proposal that the last step during catalysis involves a ferric hydroxide reacting with a methylphosphonate radical.
- 23 June 2010
- Published by Wiley in Biopolymers
- Vol. 93 (9) , 802-810
Probing the active site of MIO‐dependent aminomutases, key catalysts in the biosynthesis of β‐amino acids incorporated in secondary metabolites
The tyrosine aminomutase SgTAM produces (S)‐ß‐tyrosine from L‐tyrosine in the biosynthesis of the enediyne antitumor antibiotic C‐1027. This conversion is promoted by the methylideneimidazole‐5‐one (MIO) prosthetic group. MIO was first identified in the homologous family of ammonia lyases, which deaminate aromatic amino acids to form α,ß‐unsaturated carboxylates. Studies of substrate specificity have been described for lyases but there have been limited reports in altering the substrate specificity of aminomutases. Furthermore, it remains unclear as to what structural properties are responsible for catalyzing the presumed readdition of the amino group into the α,ß‐unsaturated intermediates to form ß‐amino acids. Attempts to elucidate specificity and mechanistic determinants of SgTAM have also proved to be difficult as it is recalcitrant to perturbations to the active site via mutagenesis. An X‐ray cocrystal structure of the SgTAM mutant of the catalytic base with L‐tyrosine verified important substrate binding residues as well as the enzymatic base. Further mutagenesis revealed that removal of these crucial interactions renders the enzyme inactive. Proposed structural determinants for mutase activity probed via mutagenesis, time‐point assays and X‐ray crystallography revealed a complicated role for these residues in maintaining key quaternary structure properties that aid in catalysis. © 2010 Wiley Periodicals, Inc. Biopolymers 93: 802–810, 2010.
- 23 June 2010
- Published by Wiley in Biopolymers
- Vol. 93 (9) , 802-810
Probing the active site of MIO‐dependent aminomutases, key catalysts in the biosynthesis of β‐amino acids incorporated in secondary metabolites
The tyrosine aminomutase SgTAM produces (S)‐ß‐tyrosine from L‐tyrosine in the biosynthesis of the enediyne antitumor antibiotic C‐1027. This conversion is promoted by the methylideneimidazole‐5‐one (MIO) prosthetic group. MIO was first identified in the homologous family of ammonia lyases, which deaminate aromatic amino acids to form α,ß‐unsaturated carboxylates. Studies of substrate specificity have been described for lyases but there have been limited reports in altering the substrate specificity of aminomutases. Furthermore, it remains unclear as to what structural properties are responsible for catalyzing the presumed readdition of the amino group into the α,ß‐unsaturated intermediates to form ß‐amino acids. Attempts to elucidate specificity and mechanistic determinants of SgTAM have also proved to be difficult as it is recalcitrant to perturbations to the active site via mutagenesis. An X‐ray cocrystal structure of the SgTAM mutant of the catalytic base with L‐tyrosine verified important substrate binding residues as well as the enzymatic base. Further mutagenesis revealed that removal of these crucial interactions renders the enzyme inactive. Proposed structural determinants for mutase activity probed via mutagenesis, time‐point assays and X‐ray crystallography revealed a complicated role for these residues in maintaining key quaternary structure properties that aid in catalysis. © 2010 Wiley Periodicals, Inc. Biopolymers 93: 802–810, 2010.
- 1 October 2009
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 13 (4) , 460-468
Structure and chemistry of 4-methylideneimidazole-5-one containing enzymes
- 1 October 2009
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 13 (4) , 460-468
Structure and chemistry of 4-methylideneimidazole-5-one containing enzymes
- Open Access
- 1 May 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (21) , 14694-14702
Regiospecific O-Methylation of Naphthoic Acids Catalyzed by NcsB1, an O-Methyltransferase Involved in the Biosynthesis of the Enediyne Antitumor Antibiotic Neocarzinostatin
- 1 May 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (21) , 14694-14702
Open AccessRegiospecific O-Methylation of Naphthoic Acids Catalyzed by NcsB1, an O-Methyltransferase Involved in the Biosynthesis of the Enediyne Antitumor Antibiotic Neocarzinostatin
- 1 December 2007
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 129 (51) , 15744-15745
The Mechanism of MIO-Based Aminomutases in β-Amino Acid Biosynthesis
β-Amino acids are widely used building blocks in both natural and synthetic compounds. Aromatic β-amino acids can be biosynthesized directly from proteinogenic α-amino acids by the action of MIO (4-methylideneimidazole-5-one)-based aminomutase enzymes. The uncommon cofactor MIO plays a role in both ammonia lyases and 2,3-aminomutases; however, the precise mechanism of the cofactor has not been resolved. Here we provide evidence that the electrophilic cofactor uses covalent catalysis through the substrate amine to direct the elimination and subsequent readdition of ammonia. A mechanism-based inhibitor was synthesized and the X-ray cocomplex structure was determined to 2.0 Å resolution. The inhibitor halts the chemistry of the reverse reaction, providing a stable complex that establishes the mode of substrate binding and the importance of tyrosine 63 in the chemistry. The proposed mechanism is consistent with the biochemistry of aminomutases and ammonia lyases and provides strong support for an amine-adduct mechanism of catalysis for this enzyme class.
- 1 December 2007
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 129 (51) , 15744-15745
The Mechanism of MIO-Based Aminomutases in β-Amino Acid Biosynthesis
β-Amino acids are widely used building blocks in both natural and synthetic compounds. Aromatic β-amino acids can be biosynthesized directly from proteinogenic α-amino acids by the action of MIO (4-methylideneimidazole-5-one)-based aminomutase enzymes. The uncommon cofactor MIO plays a role in both ammonia lyases and 2,3-aminomutases; however, the precise mechanism of the cofactor has not been resolved. Here we provide evidence that the electrophilic cofactor uses covalent catalysis through the substrate amine to direct the elimination and subsequent readdition of ammonia. A mechanism-based inhibitor was synthesized and the X-ray cocomplex structure was determined to 2.0 Å resolution. The inhibitor halts the chemistry of the reverse reaction, providing a stable complex that establishes the mode of substrate binding and the importance of tyrosine 63 in the chemistry. The proposed mechanism is consistent with the biochemistry of aminomutases and ammonia lyases and provides strong support for an amine-adduct mechanism of catalysis for this enzyme class.